期刊文献+

塞来昔布的药理作用、药代动力学及临床评价 被引量:17

Evaluation of the Pharmacological Action, Pharmacokinetics and Clinical Efficacy of Celecobix
下载PDF
导出
摘要 目的:评价特异性环氧酶抑制剂——塞来昔布的药理作用、药代动力学及临床疗效。方法:评述国内、外近期有关塞来昔布的文献。结果:推荐剂量的塞来昔布治疗骨关节炎和风湿性关节炎疗效与传统的非甾体抗炎药物(NSAIDs)相似,疗效确切,但较少引起胃肠道溃疡,且不延长出血时间,耐受性良好。结论:塞来昔布与目前国内、外广泛应用的NSAIDs相比,疗效确切,降低了胃肠道损伤的发生率,与治疗高血压、糖尿病等药物联用,没有明显的药物相互作用。 OBJECTIVE: To evaluate the pharmacological action, pharmacokinetics and therapeutic efficacy of Celecobix, a specific epioxidase inhibiting agent .METHODS: To review the relevent literature reported at home and abroad in recent years.RESULTS: The therapeutic effects of Celecobix in recommended dosage on osteoarthritis and rheumatic arthritis were comparable to those of traditional NSAIDs, and Celecobix induced less gastroenteric ulcers, did not prolong the bleeding time and was tolerable to patients.CONCLUSION: Compared with NSAIDs which are extensively used at home and abroad, Celecobix is satisfactory in therapeutic effect and can reduce the incidence of gastroenteric ulcers,moreover,it does not interact with the drugs for hypertension or diabetes.
出处 《中国医院用药评价与分析》 2002年第5期271-276,共6页 Evaluation and Analysis of Drug-use in Hospitals of China
关键词 塞来昔布 药理作用 药代动力学 临床评价 Celecobix pharmacological action pharmacokinetics clinical evaluation
  • 相关文献

参考文献10

  • 1Ryn JV, Pairet M Clinical experience with cyclooxyge_ nase- 2 inhibitor[J] Inflamm Res, 1999, 48: 247 被引量:1
  • 2Hawkey CJ COX- 2 inhibitors[J] Lancet, 1999, 353: 307 被引量:1
  • 3Simon LS Role and regulation of cyclooxygenase- 2 du_ ring inflammation[J] Am J Med, 1999, 106(5): 37 被引量:1
  • 4Lanza FL, Rack MF, Callison DA, et al A pilot endosco_ pic study of the gastroduodental effect of SC- 58635[J] Gasteroenterology, 1997, 112: 194 被引量:1
  • 5Simon LS, Lanza FL, Lipsky PE, et al Preliminary stu_ dy of the safety and efficacy of SC- 58635 a noval cycl_ ooxygenase- 2 inhibitor: efficacy and safety in two plac_ ebo- controlled trials in osteoafthritis and rheumatoid arthritis, and study of gastrointestinal and platelet effec ts[J] Arthritis Rheum, 1998, 41: 1 591 被引量:1
  • 6Goldstein JL, Silverstein FE, Agrawal NM, et al Redu_ ced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX- 2 inhibitor[J] Am J Ga_ stroenterol, 2000, 95(7): 1 681 被引量:1
  • 7李玉珍,王佩.新型非甾体抗炎药——罗非昔布[J].药物不良反应杂志,2000,2(4):271-272. 被引量:1
  • 8Andrew W, John GF, Joseph AP, et al Cyclooxygenase- 2- specific inhibitors and cardiorenal function: a rando_ mized, controlled trial of celecoxib and rofecoxib in old_ er hypertensive osteoarthritis patients, For SUCCESS VI Study Group[J] American Journal of Therapeutics, 2001, 8: 85 被引量:1
  • 9Lefkowith JB Cyclooxygenase- 2 specificity and its cl_ inical implication[J] Am J Med, 1999, 106(5): 43 被引量:1
  • 10Leese PT, Hubbard RC, Karim A, et al Effects of celec_ oxib, a novel cyclooxygenase- 2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial[J] J Clin Pharmacol, 2000, 40: 124 被引量:1

二级参考文献10

  • 1黄世杰.默克公司为Rofecoxib提交美国新药申请[J].国外医学:药学分册,1999,26(4):252-253. 被引量:3
  • 2Hawkey CJ. COX-2 inhibitors. Lancet, 1999,353:307. 被引量:1
  • 3Ehrich EW, Dallob A, De Lepeleire , et al. Characterisation of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther, 1999,65(4):336. 被引量:1
  • 4Van Hecken A, Depre M, Ehrich E, et al.Demonstration of specific COX-2 inhibitor by MK-996 in humans with supratherapeutic doses.Clin Pharmacol Ther, 1999,65(2):164. 被引量:1
  • 5Lesley J. Scott, Harriet M. Lamb, Rofecoxib.Drugs, 1999, 58(3):499. 被引量:1
  • 6Cannon G, Caldwell J, Holt P, et al. MK-0966,a specific COX-2 inhibitor, has clinical efficacy comparable to dielofenae in the treatment of knee and hip osteoarthritis (OA) in a 26-week controlled clinical trial. Arthritis Rheum, 1998, 41(Suppl 9):S83. 被引量:1
  • 7Saag K, Fisher C, Mckay J, et al. MK-0966, a specific COX-2 inhibitor, has clinical efficacy comparable to ibuprofen in the treatment of knee and hip osteoarthritis (OA) in a 6-week controlled clinical trial.Arthritis Rheum, 1998, 41(Suppl 9):S84. 被引量:1
  • 8Ehrich E, Schnitzer T, Kiviz A, et al.MK-0966, a highly selective COX-2 inhibitor, was effective in the treatment of osteoarthritis of the knee and hip in a 6-week placebo controlled study.Arthritis Rheum, 1997,40 Suppl:85. 被引量:1
  • 9Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a eyeloxyge-nase-2 specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology, 1999,117(4):776. 被引量:1
  • 10黄世杰.FDA支持rofecoxib由于骨关节炎与急性疼痛[J].国外医学:药学分册,1999,26(6):370-370. 被引量:1

同被引文献144

引证文献17

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部